Incannex Healthcare Inc ADR IXHL

$2.64 +0.04 (1.54%)

Valuation

Market cap
32,617,000
Revenue TTM
$0
Net income TTM
$-19,300,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
40,200
Avg volume
82,928
Day's range
$2.57 – $2.69
Shares out
12,545,000
Stochastic %K
20%
Beta
6.97
Analysts
Strong Buy
Price target
$18.00

Price

Company profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treat...

Show more

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
61 4 0984 0786
Website
https://www.incannex.com
Address
Rialto South Tower Level 23, 525 Collins Street Norwest, Melbourne, Australia

Latest news

Stocktwits

SeamsOF Oct 24, 1:38 AM
$IXHL gotta agree
0 replies
MastermindTrader Oct 23, 8:53 PM
Put FMFC on your watchlist for next week. 💎 FMFC has barely 450 watchers on Stocktwits and large social media accounts are covering it. Webull data showing that FMFC has only 492k shares outstanding and 242k shares float. $GOVX $IXHL $MRNA ++
0 replies
Awesomeaastroem Oct 23, 8:03 PM
$IXHL I’m 2.69% richer today than I was yesterday! Watch out Elon, I’m coming for you.
0 replies
richkid_26 Oct 23, 7:51 PM
$IXHL 👀👀👀
1 replies
malibu_rum67 Oct 23, 4:15 PM
$IXHL …. 💪💪💪
0 replies
OtCjimmy Oct 23, 2:09 PM
$IXHL notice those who say "it's such a blessing to be offered shares at this price" said that many many many times before. Don't get led to the slaughter, folks! Joel is as dumb a CEO as you can find.
0 replies
RogueFF7 Oct 23, 2:05 PM
$IXHL Good Friday morning Bulls. Hopefully we see an 8K soon. Have a great weekend.
1 replies
RogueFF7 Oct 23, 1:20 PM
$IXHL Technical Analysis of the Commentary 1. The Bohr Effect Argument is Mechanistically Sound: The author accurately notes how acetazolamide-induced mild metabolic acidosis decreases hemoglobin oxygen affinity, facilitating oxygen release to hypoxemic tissues during airway blockages. This explains why IHL-42X punches above its weight in tissue oxygenation metrics compared to purely mechanical/neuromuscular agents. 2. Regulatory Hierarchical Gating is a Critical Detail: Highlighting Apnimed's failure on the PROMIS-Fatigue endpoint is a crucial regulatory point. In FDA filings, once a hierarchical endpoint fails, subsequent p-values lose formal inferential validity, converting potential labeling claims into unproved secondary observations. If DReAMzz delivers clean, non-skewed results that confirm or improve on the RePOSA signals (especially oxygen metrics + solid responder rates with good tolerability), it would be a meaningful de-risking event for IHL-42X.
1 replies